Ajay Srinivasan, Pradip Devhare, Dadasaheb Akolkar*, Darshana Patil, Vineet Datta, Ashwini Ghaisas, Chirantan Bose, Shankar Somashekar, Revati Patil, Jinumary John, Sanket Patil, Sachin Apurwa, Navin Srivastava and Rajan Datar
Department of Cancer, Datar Cancer Genetics Limited, IndiaFulltext PDF
We present here the case of a 61-year old male smoker diagnosed with aggressive metastatic Squamous Cell Carcinoma (SCC) of the Lung. The disease had progressed following failure of prior systemic lines of Standard of Care (SoC) therapies. Freshly biopsied tumor samples were obtained and used for multi-analyte molecular and functional interrogation of the tumor (ETA: Encyclopedic Tumor Analysis). Based on findings of ETA, iterations of de novo combination therapy regimen were administered to the patient to counter disease evolution, emergent drug resistance and disease progression. Based on such personalization of treatment regimen, timely therapeutic course correction could be effectively achieved. This case shows that ETA-guided sequential personalized prescription of cytotoxic and targeted therapies helped to counter disease progression at each
instance and led to durable treatment response for 15 months.
SCC; Lung; Personalized treatment; FGFR1; Pazopanib
Srinivasan A, Devhare P, Akolkar D, Patil D, Datta V, Ghaisas A, et al. Long Overall Survival in a Case of Refractory Stage IV Squamous Cell Carcinoma of Lung Treated with Personalized De Novo Combination Regimen. Clin Case Rep Int. 2020;4:1180..